Prostatic Neoplasms clinical trials

The registry lists 7,046 studies for Prostatic Neoplasms across more than 10 countries. 1,580 are recruiting or about to start. 6,091 of them are mainly about Prostatic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Prostatic Neoplasms, Castration-Resistant too: 7,098 studies, 1,590 open.

ClinicalTrials.gov finds 7,648 studies for Prostatic Neoplasms. How that becomes 7,040 here

This page counts the studies the registry files under Prostatic Neoplasms, and those it files under no condition that list Prostatic Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

7,648Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−52Filed under a narrower condition, counted on its own pageProstatic Neoplasms, Castration-Resistant 52
−146List Prostatic Neoplasms as a condition, but the registry did not file them under itMost often written as “Metastatic Castration-resistant Prostate Cancer” (20), “Castration-resistant Prostate Cancer” (17), and “Prostate Cancer Metastatic” (14). The registry filed them under other conditions only, most often Carcinoma, Non-Small-Cell Lung (32) and Triple Negative Breast Neoplasms (23).
−410Match it another way234 name it in the title, 29 in a keyword, and 147 by a synonym or other text the search reads.
7,040The count on this page584 of them list Prostatic Neoplasms in their own words; the registry filed them under no condition.

Get an email when these change. Save the Prostatic Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 3,264
Recruiting: 1,228
Terminated: 668
Active, not recruiting: 619
Status unknown: 595
Not yet recruiting: 297

Phase

Phase 2: 2,161
Phase 1: 1,223
Phase 3: 650
Phase 4: 136
Early Phase 1: 126

Where

United States: 3,595
Canada: 711
China: 539
France: 509
United Kingdom: 486
Italy: 337

Who runs them

National Cancer Institute (NCI) (202) · Memorial Sloan Kettering Cancer Center (138) · M.D. Anderson Cancer Center (124) · University Health Network, Toronto (101) · AstraZeneca (85) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (78) · Bayer (75) · Mayo Clinic (71)

What is being tested here

Drugs under test in Prostatic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Darolutamide	24	8	49
Lutetium (¹⁷⁷Lu) vipivotide tetraxetan	19	3	35
Abiraterone	13	9	108
Docetaxel	12	30	176
Enzalutamide	11	13	93
Abiraterone Acetate	9	8	85
Leuprolide	8	25	66
Apalutamide	8	14	59
Gallium 68 PSMA-11	8	12	48
Carboplatin	8	2	31

Drug classes tested here Antiandrogens 48 open · Antimitotic agents 17 open · PARP inhibitors 16 open · Immune checkpoint inhibitors 8 open · Tyrosine kinase inhibitors (TKIs) 7 open

Coming up

200phase 3 studies under way

626studies finish main data collection within a year44 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy · Phase 3 · Ottawa Hospital Research Institute
Nov 2026Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial · Phase 3 · NRG Oncology
Nov 2026Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms · Phase 3 · Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Dec 2026A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients · Phase 3 · Shanghai Jiao Tong University School of Medicine
Dec 2026Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation · Phase 3 · Region Västerbotten
Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer · Phase 3 · Karolinska Institutet
Dec 2026A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy · Phase 3 · Janssen Research & Development, LLC
Dec 2026COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer · Phase 3 · Samsung Medical Center
Dec 202664Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer · Phase 3 · Clarity Pharmaceuticals Ltd
Dec 2026Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer · Phase 3 · University of Sydney

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 928 (76%) set no upper age limit and 76 (6%) stop at 75 or younger. 67 (5%) take children under 18. 0 (0%) are for women only and 1,002 (82%) for men only; 82 (7%) take healthy volunteers.

Recruiting studies that take each age, of 1,228
Age	Women	Men
10	17 (1%)	64 (5%)
18	205 (17%)	1,030 (84%)
30	217 (18%)	1,086 (88%)
40	222 (18%)	1,160 (94%)
50	223 (18%)	1,207 (98%)
65	225 (18%)	1,223 (100%)
75	225 (18%)	1,206 (98%)
85	204 (17%)	1,080 (88%)

Across all 7,046 studies, recruiting or not: 7% stop at 75 or younger and 1% at 65; 9% take children; <1% are for women only and 84% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Prostatic Neoplasms studies take

Of 724 phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	43 mo23–68 · 455 studies	37 mo20–62 · 212 studies	46 mo27–76 · 243 studies
Phase 1/2	61 mo30–85 · 210 studies	52 mo35–… · 96 studies	65 mo28–85 · 114 studies
Phase 2	53 mo34–80 · 724 studies	35 mo21–45 · 114 studies	57 mo39–86 · 610 studies
Phase 2/3	115 mo32–… · 43 studies	—	—
Phase 3	57 mo31–100 · 265 studies	38 mo23–53 · 126 studies	99 mo57–144 · 139 studies
Phase 4	41 mo28–67 · 52 studies	—	—
Interventional, no phase	43 mo22–84 · 1,155 studies	47 mo16–72 · 57 studies	43 mo22–86 · 1,098 studies
Observational	60 mo29–141 · 650 studies	45 mo24–65 · 109 studies	67 mo29–162 · 541 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out